Daré Bioscience signs deal with the Gates Foundation

Daré Bioscience, a health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, has won a contract with the Gates Foundation under which it can receive up to approximately US$300,000.

The deal will see it  conduct a strategic landscape review of organisations with capabilities relevant to contraceptive product development.

Daré will work to identify and assess for-profit and non-profit organisations worldwide with demonstrated capabilities in formulation development, clinical and commercial manufacturing, clinical trial design, and regulatory support for contraceptive products.

“We are honored to be selected to receive funding from the Gates Foundation to help strengthen the global contraceptive innovation ecosystem,” said Sabrina Martucci Johnson, president and CEO of Daré Bioscience.

“Daré’s mission is to close critical gaps in care using rigorous science and technologies that serve her needs. This initiative will help identify potential strategic partners for the foundation that can help to accelerate the translation of new contraceptive concepts into products that make a meaningful difference globally.”

“This initiative builds on Daré’s expertise in women’s health product development and its track record of working with public and private sector collaborators to advance innovative contraceptive and reproductive health solutions,” added Johnson.